2 3 7 8-Tetrachlorodibenzo-P-Dioxin Aconitum Napel
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- 2 3 7 8-Tetrachlorodibenzo-P-Dioxin Aconitum Napel
- Multi-Substance Complex (TW-UNKNOWN-multi): Insufficient Data for Repurposing Evaluation
Multi-Substance Complex (TW-UNKNOWN-multi): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This entry corresponds to a multi-substance identifier comprising 23 components — ranging from homeopathic botanicals (e.g., Arnica montana, Apis mellifera, Calendula) to industrial chemicals (e.g., benzene, dioxin, hydrogen cyanide) — that could not be resolved to a single drug entity. No original indication, no regulatory approval in Taiwan, and no TxGNN-predicted indications were returned. The evidence base is effectively empty (L5), and this entry cannot be meaningfully evaluated for drug repurposing at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — no prediction generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Is Available
The drug INN field contains a semicolon-delimited list of 23 heterogeneous substances:
| # | Substance | Category |
|---|---|---|
| 1 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) | Industrial toxin / Environmental contaminant |
| 2 | Aconitum napellus whole | Toxic botanical / Homeopathic ingredient |
| 3 | Ammonium cation | Inorganic ion |
| 4 | Apis mellifera | Homeopathic ingredient (bee venom) |
| 5 | Arnica montana whole | Homeopathic botanical |
| 6 | Arsenic trioxide | Approved anticancer agent (AML) |
| 7 | Benzene | Industrial carcinogen |
| 8 | Calendula officinalis flowering top | Homeopathic botanical |
| 9 | Chlorine | Industrial chemical / Toxin |
| 10 | Chloroform | Industrial solvent / Hepatotoxin |
| 11 | Dieffenbachia seguine whole | Toxic plant |
| 12 | Fenson | Obsolete acaricide / Pesticide |
| 13 | Fluorine | Reactive element |
| 14 | Hydrogen cyanide | Highly toxic gas |
| 15 | Methane | Combustible gas |
| 16 | Nitric acid | Strong acid |
| 17 | Onion | Food / Homeopathic ingredient |
| 18 | Phosfolan | Organophosphate pesticide |
| 19 | Potassium cyanide | Highly toxic salt |
| 20 | Propane | Combustible gas |
| 21 | Sulfur | Mineral / Homeopathic ingredient |
| 22 | Sulfuric acid | Strong acid |
| 23 | Veratrum album root | Toxic botanical |
This mixture of industrial chemicals, environmental toxins, pesticides, and homeopathic botanicals does not correspond to any identifiable single drug entity. The TxGNN pipeline requires a resolvable DrugBank ID to generate knowledge-graph embeddings; since drugbank_id is null and the INN string could not be mapped, no prediction was produced.
The most plausible data pipeline issue is that multiple FDA product ingredient lists were concatenated without deduplication, generating a meaningless compound key. The candidate ID TW-UNKNOWN-multi supports this hypothesis.
Conclusion and Next Steps
Decision: Hold
Rationale: This entry does not represent a real drug candidate. It is a pipeline artifact — a concatenated multi-ingredient string that failed to resolve to any single pharmacological entity — and cannot be assessed for repurposing potential.
To proceed, the following is needed:
- Deduplication and parsing: Split the concatenated INN string at the source and create one candidate record per distinct active ingredient.
- Identity resolution: Re-run DrugBank mapping on each individual substance (e.g., Arsenic trioxide → DB01169, which has known oncology use and may be a legitimate repurposing candidate).
- Data provenance audit: Investigate why
TW-UNKNOWN-multiwas generated — likely a bug in the Taiwan FDA data ingestion step where a multi-ingredient product’s ingredient list was flattened into the INN field. - Exclusion of non-drug substances: Industrial chemicals (benzene, TCDD, HCN), gases (methane, propane), and strong acids (sulfuric acid, nitric acid) should be excluded from the repurposing pipeline entirely, as they have no therapeutic application.
- Homeopathic ingredient handling: Substances such as Arnica montana, Calendula officinalis, and Apis mellifera may require a dedicated homeopathic product pipeline with separate evaluation criteria.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.